You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

  • Technology appraisal guidance
  • Reference number: TA462
  • Published:  26 July 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Appraisal committee members and NICE project team
  • Update information

3 Evidence

The appraisal committee considered evidence submitted by Bristol-Myers Squibb and a review of this submission by the evidence review group. See the committee papers for full details of the evidence.


Next page 4 Committee discussion Previous page 2 The technology
Back to top